(+/-)-(4aS,8aS,10aR)-1,1,4a,8a-tetramethyl-2,6-dioxo-1,2,4a,6,7,8,8a,9,10,10a-decahydrophenanthrene-3-carbonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: (+/-)-(4aS,8aS,10aR)-1,1,4a,8a-tetramethyl-2,6-dioxo-1,2,4a,6,7,8,8a,9,10,10a-decahydrophenanthrene-3-carbonitrile
• 英文别名: TBE-10；(4aR,8aR,10aS)-1,1,4a,8a-tetramethyl-2,6-dioxo-8,9,10,10a-tetrahydro-7H-phenanthrene-3-carbonitrile
• 化学式: C₁₉H₂₃NO₂
• 分子量: 297.397
• InChiKey: GTWIHHXFFORGMI-MDASCCDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  57.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (+)-(4aS)-4,4a,5,6,7,8-hexahydro-1,4a-dimethyl-naphthalen-2(3H)-one 在 chromium(VI) oxide 、 甲醇 、 叔丁基过氧化氢 、 盐酸羟胺 、 氨 、 sodium methylate 、 lithium 、 sodium hydride 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 mineral oil 、 苯 为溶剂， 生成 (+/-)-(4aS,8aS,10aR)-1,1,4a,8a-tetramethyl-2,6-dioxo-1,2,4a,6,7,8,8a,9,10,10a-decahydrophenanthrene-3-carbonitrile
  参考文献：
  名称：

  Tricyclic Compounds Containing Nonenolizable Cyano Enones. A Novel Class of Highly Potent Anti-Inflammatory and Cytoprotective Agents

  摘要：

  Forty-four novel tricycles containing nonenolizable cyano enones (TCEs) were designed and synthesized on the basis of a semisynthetic pentacyclic triterpenoid, bardoxolone methyl, which is currently being developed in phase II clinical trials for the treatment of severe chronic kidney disease in diabetic patients. Most of the TCEs having two different kinds of nonenolizable cyano enones in rings A and C are highly potent suppressors of induction of inducible nitric oxide synthase stimulated with interferon-gamma and are highly potent inducers of the cytoprotective enzymes heme oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Among these compounds, (+/-)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile ((+/-)-31) is the most potent in these bioassays in our pool of drug candidates including semisynthetic triterpenoids and synthetic tricycles. These facts strongly suggest that an essential factor for potency is not a triterpenoid skeleton but the cyano enone functionality. Notably, TCE 31 reduces hepatic tumorigenesis induced with aflatoxin in rats. Further preclinical studies and detailed mechanism studies on 31 are in progress.

  DOI：

  10.1021/jm101445p

文献信息

• Tricyclic-bis-enone derivatives and methods of use thereof
  申请人：——

  公开号：US20030232786A1

  公开（公告）日：2003-12-18

  Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.

  提供了新型三环双烯酮衍生物（TBEs）以及制备此类TBEs的方法。还提供了用于预防和/或治疗癌症、阿尔茨海默病、帕金森病、多发性硬化症、肌萎缩侧索硬化、类风湿性关节炎、炎症性肠病以及所有其他疾病的方法，这些疾病的发病机制被认为涉及过量产生一氧化氮（NO）或前列腺素或iNOS或COX-2基因或基因产物的过度表达。此外，本发明的TBE化合物的合成方法利用廉价的商业可获得试剂，具有高成本效益且易于扩展。还提供了利用新型中间体的高效合成方法以及这些中间体的合成。此外，本发明还提供了设计新型水溶性TBEs的方法。
• Tricyclic Compounds Containing Nonenolizable Cyano Enones. A Novel Class of Highly Potent Anti-Inflammatory and Cytoprotective Agents
  作者：Tadashi Honda、Hidenori Yoshizawa、Chitra Sundararajan、Emilie David、Marc J. Lajoie、Frank G. Favaloro、Tomasz Janosik、Xiaobo Su、Yukiko Honda、Bill D. Roebuck、Gordon W. Gribble

  DOI：10.1021/jm101445p

  日期：2011.3.24

  Forty-four novel tricycles containing nonenolizable cyano enones (TCEs) were designed and synthesized on the basis of a semisynthetic pentacyclic triterpenoid, bardoxolone methyl, which is currently being developed in phase II clinical trials for the treatment of severe chronic kidney disease in diabetic patients. Most of the TCEs having two different kinds of nonenolizable cyano enones in rings A and C are highly potent suppressors of induction of inducible nitric oxide synthase stimulated with interferon-gamma and are highly potent inducers of the cytoprotective enzymes heme oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Among these compounds, (+/-)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile ((+/-)-31) is the most potent in these bioassays in our pool of drug candidates including semisynthetic triterpenoids and synthetic tricycles. These facts strongly suggest that an essential factor for potency is not a triterpenoid skeleton but the cyano enone functionality. Notably, TCE 31 reduces hepatic tumorigenesis induced with aflatoxin in rats. Further preclinical studies and detailed mechanism studies on 31 are in progress.